Payment overview · 2025
General Payments
$305.14
15 reported records · 9 companies
Healthcare provider profile · identity verified
Alexander L Thacker, M.D
Allopathic & Osteopathic Physicians|Family Medicine · BRADENTON, FL · NPI 1902152358
Verified facts
What the public records show
CMS Open Payments records show Alexander L Thacker, M.D received $305.14 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.86 | 25.8% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $66.73 | 21.9% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.03 | 14.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.34 | 8.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.10 | 8.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.73 | 6.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.51 | 5.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.82 | 4.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.02 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.14 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $66.73 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.60 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $25.34 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 769 | 228 |
| Losartan Potassium | Losartan Potassium | 459 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 415 | 127 |
| Omeprazole | Omeprazole | 412 | 129 |
| Lisinopril | Lisinopril | 389 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 381 | 121 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 86 |
| Simvastatin | Simvastatin | 283 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 75 |
| Metformin Hcl | Metformin Hcl | 224 | 63 |
| Alprazolam | Alprazolam | 197 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 61 |
| Sertraline Hcl | Sertraline Hcl | 183 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 49 |
| Eliquis | Apixaban | 147 | 38 |
| Famotidine | Famotidine | 146 | 42 |
| Trazodone Hcl | Trazodone Hcl | 142 | 41 |
| Allopurinol | Allopurinol | 140 | 37 |
| Meloxicam | Meloxicam | 136 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 59 |
| Metformin Hcl Er | Metformin Hcl | 135 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 36 |
| Valsartan | Valsartan | 127 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 40 |
| Montelukast Sodium | Montelukast Sodium | 126 | 39 |
| Ozempic | Semaglutide | 106 | 16 |
| Lorazepam | Lorazepam | 102 | 31 |
| Synthroid | Levothyroxine Sodium | 102 | 26 |
| Atenolol | Atenolol | 99 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 36 |
| Baclofen | Baclofen | 94 | 33 |
| Furosemide | Furosemide | 93 | 32 |
| Finasteride | Finasteride | 92 | 27 |
| Gabapentin | Gabapentin | 91 | 29 |
| Celecoxib | Celecoxib | 85 | 30 |
| Bupropion Xl | Bupropion Hcl | 84 | 24 |
| Prednisone | Prednisone | 83 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 19 |
| Jardiance | Empagliflozin | 82 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 33 |
| Potassium Chloride | Potassium Chloride | 73 | 26 |
| Pregabalin | Pregabalin | 73 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 23 |
| Clonazepam | Clonazepam | 70 | 18 |
| Rybelsus | Semaglutide | 69 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 21 |
| Mounjaro | Tirzepatide | 63 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 52 |
| Ezetimibe | Ezetimibe | 62 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 21 |
| Ketoconazole | Ketoconazole | 60 | 38 |
| Estradiol | Estradiol | 58 | 18 |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Diazepam | Diazepam | 50 | 18 |
| Tramadol Hcl | Tramadol Hcl | 50 | 21 |
| Carvedilol | Carvedilol | 47 | 16 |
| Lovastatin | Lovastatin | 47 | 12 |
| Valacyclovir | Valacyclovir Hcl | 47 | 24 |
| Cefdinir | Cefdinir | 46 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 30 |
| Donepezil Hcl | Donepezil Hcl | 40 | 14 |
| Hydrocortisone | Hydrocortisone | 40 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Ramipril | Ramipril | 38 | 11 |
| Spironolactone | Spironolactone | 37 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Buspirone Hcl | Buspirone Hcl | 36 | 21 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 27 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 19 |
| Fluconazole | Fluconazole | 33 | 14 |
| Cephalexin | Cephalexin | 32 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 19 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 11 |
| Azithromycin | Azithromycin | 22 | 20 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Glimepiride | Glimepiride | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.14 · 15 records | ABBVIE INC. | AIRSUPRA, CREON, HYQVIA, INGREZZA, Korlym, LINZESS, MOUNJARO, ONPATTRO, QULIPTA, UBRELVY, VIBERZI, VYEPTI, WaveWriter Alpha Prime 16, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error